

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137093 A1

(51) International Patent Classification:

A61K 38/20 (2006.01) *C07K 16/28* (2006.01)
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
C07K 14/55 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2024/060756

(22) International Filing Date:

18 December 2024 (18.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/612,007 19 December 2023 (19.12.2023) US

(71) Applicant: **CEPHALON LLC** [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US).

(72) Inventors: **AYTON, Paul**; 610 Galveston Drive, Redwood City, CA 94063 (US). **WILSON, David, S., Jr.**; 610 Galveston Drive, Redwood City, CA 94063 (US).

(74) Agent: **MIRON, Anna**; 1735 Market Street, Suite 3300, Philadelphia, PA 19103-7501 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: USES FOR ATTENUATED IL-2 IMMUNOCONJUGATES

(57) Abstract: Disclosed herein are methods of treating a cancer in a subject using an anti-hPD-1 antibody-modified human interleukin-2 (hIL-2) immunoconjugate alone or in combination with an antagonistic anti-PD-1 antibody.



WO 2025/137093 A1